Second Circuit Sends Quincy Bioscience Back To The Lab

Conflicting claims in scientific studies not enough to dismiss Prevagen case

Remember This One?

The Second Circuit Court of Appeals breathed new life into a joint complaint by the Federal Trade Commission (FTC or Commission) and the state of New York against Quincy Bioscience, a "biotechnology company focused on the discovery, development and commercialization of novel technologies to support cognitive function and other normal health challenges associated with aging."

The original complaint dealt with Quincy's flagship product, Prevagen, which the company had been marketing as a memory-improvement supplement. Quincy bolstered these claims with what it called the Madison Memory Study, which it claimed was "a landmark double-blind and placebo controlled" study.